Paul Bolno Sells 10,480 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences Ltd. (NASDAQ:WVE) CEO Paul Bolno sold 10,480 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $140,956.00. Following the sale, the chief executive officer owned 275,520 shares of the company’s stock, valued at $3,705,744. This trade represents a 3.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

WAVE Life Sciences Trading Down 3.5%

NASDAQ:WVE opened at $12.80 on Friday. The stock’s 50 day simple moving average is $15.09 and its 200-day simple moving average is $10.39. WAVE Life Sciences Ltd. has a 12-month low of $5.28 and a 12-month high of $21.73. The firm has a market cap of $2.14 billion, a P/E ratio of -17.07 and a beta of -1.78.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%. The firm had revenue of $7.61 million during the quarter, compared to analyst estimates of $9.85 million. Research analysts forecast that WAVE Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Key Headlines Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Wells Fargo kept an “overweight” rating on WVE and set a $27 price target (down from $29), which still implies substantial upside versus the current share price — a signal that some sell‑side analysts remain constructive on the company’s pipeline and long‑term prospects. The Fly: Wells Fargo price target note
• Positive Sentiment: Broader analyst coverage remains favorable — multiple firms have upgraded or raised targets in recent months and the consensus remains skewed toward Buy/Outperform, supporting potential upside if clinical progress continues. MarketBeat analyst roundup
• Neutral Sentiment: Institutional ownership is very high (~90%), which means large holders dominate supply — that can both support the stock during positive news and amplify moves when those holders change positions.
• Negative Sentiment: Multiple insiders sold shares on Feb 9 (CEO Paul Bolno, CFO Kyle Moran, and other officers/directors), executing sizable sales at roughly $13.45 per share — the cluster of top‑executive sales is being viewed negatively by the market as a potential signal of near‑term insider liquidity. InsiderTrades alert
• Negative Sentiment: WAVE’s last reported quarter missed estimates (EPS and revenue) and the company remains unprofitable with wide negative margins — ongoing cash burn and execution risk keep the shares sensitive to clinical and revenue updates. MarketBeat: earnings summary

Wall Street Analyst Weigh In

WVE has been the topic of several recent analyst reports. Royal Bank Of Canada upgraded shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $9.00 to $27.00 in a research report on Monday, December 8th. Cantor Fitzgerald upped their price target on WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Canaccord Genuity Group raised their price objective on WAVE Life Sciences from $40.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, February 3rd. Morgan Stanley set a $28.00 target price on WAVE Life Sciences in a research report on Monday, December 8th. Finally, Truist Financial raised their price target on WAVE Life Sciences from $36.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Fourteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.56.

Institutional Trading of WAVE Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of WVE. CWM LLC lifted its stake in shares of WAVE Life Sciences by 6,729.0% during the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock worth $36,000 after purchasing an additional 2,086 shares during the period. Bessemer Group Inc. increased its stake in WAVE Life Sciences by 1,156.3% in the third quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock valued at $72,000 after purchasing an additional 9,135 shares during the last quarter. Russell Investments Group Ltd. lifted its position in WAVE Life Sciences by 1,441.6% during the third quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock worth $73,000 after buying an additional 9,284 shares during the period. Ameritas Investment Partners Inc. boosted its stake in WAVE Life Sciences by 18.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock worth $74,000 after buying an additional 1,802 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in WAVE Life Sciences by 44.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company’s stock worth $76,000 after buying an additional 3,609 shares during the last quarter. 89.73% of the stock is owned by hedge funds and other institutional investors.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.